Alongside full PIK3CA wild-type data, Celcuity sets the bar for gedatolisib's PIK3CA-mutant readout.

Artios, Synnovation and Novartis show mere glimmers of activity.

Enhertu improves outcomes in (neo)adjuvant breast cancer, but toxicity resurfaces.

But it will be up to regulators to decide if giredestrant has done enough for an all-comers label.

Keynote-905 finds a 50% reduction in the risk of death in (neo)adjuvant muscle-invasive bladder cancer.

Boehringer’s Hernexeos and Bayer’s sevabertinib look similar in first-line HER2-mutant NSCLC.